Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA: MSK, Skin and Oral Health: Clinical Research - MSK Health

Université Laval

$100,000.00

Clinical validity and clinical utility of a screening test for Paget's disease of bone

EF 2018-19

Résumé
Paget's disease of bone (PDB) is a common bone disorder, affecting 2 to 3% of people over 55 years of age and rising up to 6% after the age of 80. This disease may lead to severe disabilities, including fractures and bone deformity. People with PDB may have no or few symptoms in 40% of cases making them hard to identify, but this disease may also lead to severe complications. Some novel drugs in use or in development for osteoporosis treatment are contraindicated in case of some common conditions, such as PDB, which often go unnoticed in patients with concomitant osteoporosis, both diseases being frequent in elderlies. With the commercialization at lower price of biosimilars of one of these drugs in 2019, a significant increase in the use of this family of therapies is expected. In this research, we aim at evaluating the validity and the utility for clinicians of a novel diagnostic test developed by our team, to detect persons affected by PDB: 1) We will test the validity of the test in a cohort of Italian participants, as well as assess whether the test may be useful to predict the severity of PDB, including its possible neoplastic complications; 2) We will evaluate the validity of the test in a subgroup of the Canadian Multicentre Osteoporosis Study cohort, this cohort reflecting the general Canadian population aged over 50 years old; 3) We will test the validity of the test at screening affected first and second degree relatives of a patient with PDB in our large French-Canadian cohort of families with PDB; and 4) We will perform a health economic evaluation of the impact of this biological test in the perspective of its use in the clinical practice. This combination of markers will help with the selection of patients and the appropriate choice of osteoporosis treatment, to improve drug safety by avoiding serious adverse events which are devastating for the patient and expensive for the healthcare system.
Programme
Project Grant - PA: MSK, Skin and Oral Health: Clinical Research - MSK Health
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
394827
Name
Michou Laetitia N
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Clinical Investigation - B 2
Projecttitle
Clinical validity and clinical utility of a screening test for Paget's disease of bone
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: MSK, Skin and Oral Health: Clinical Research - MSK Health
Keyworddelim
Bone Anabolic Treatment; Bone Biomarkers; Budget Impact Model; Clinical Utility; Clinical Validity; Drug Safety; Health Economic Evaluation; Molecular Test; Osteoporosis; Paget'S Disease Of Bone
Abstract
Paget's disease of bone (PDB) is a common bone disorder, affecting 2 to 3% of people over 55 years of age and rising up to 6% after the age of 80. This disease may lead to severe disabilities, including fractures and bone deformity. People with PDB may have no or few symptoms in 40% of cases making them hard to identify, but this disease may also lead to severe complications. Some novel drugs in use or in development for osteoporosis treatment are contraindicated in case of some common conditions, such as PDB, which often go unnoticed in patients with concomitant osteoporosis, both diseases being frequent in elderlies. With the commercialization at lower price of biosimilars of one of these drugs in 2019, a significant increase in the use of this family of therapies is expected. In this research, we aim at evaluating the validity and the utility for clinicians of a novel diagnostic test developed by our team, to detect persons affected by PDB: 1) We will test the validity of the test in a cohort of Italian participants, as well as assess whether the test may be useful to predict the severity of PDB, including its possible neoplastic complications; 2) We will evaluate the validity of the test in a subgroup of the Canadian Multicentre Osteoporosis Study cohort, this cohort reflecting the general Canadian population aged over 50 years old; 3) We will test the validity of the test at screening affected first and second degree relatives of a patient with PDB in our large French-Canadian cohort of families with PDB; and 4) We will perform a health economic evaluation of the impact of this biological test in the perspective of its use in the clinical practice. This combination of markers will help with the selection of patients and the appropriate choice of osteoporosis treatment, to improve drug safety by avoiding serious adverse events which are devastating for the patient and expensive for the healthcare system.
Competitiondate
201809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Michou, Laetitia N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~